MétaCan
Menu
Back to cohort
Record W4407316344 · doi:10.1371/journal.pgph.0004268

Global availability of medications and health technologies for kidney care: A multinational study from the ISN-GKHA

2025· article· en· W4407316344 on OpenAlexafffund
Dearbhla Kelly, Erika Jones, Zibya Barday, Silvia Arruebo, Fergus Caskey, Sandrine Damster, Jo‐Ann Donner, Vivekanand Jha, Adeera Levin, Masaomi Nangaku, Syed Saad, Marcello Tonelli, Feng Ye, Ikechi G. Okpechi, Aminu K. Bello, David W. Johnson

Bibliographic record

VenuePLOS Global Public Health · 2025
Typearticle
Languageen
FieldMedicine
TopicChronic Kidney Disease and Diabetes
Canadian institutionsUniversity of CalgaryUniversity of AlbertaUniversity of British Columbia
FundersDaiichi Sankyo EuropeMedical Research CouncilChugai PharmaceuticalAkebia TherapeuticsAstellas PharmaUniversity of AlbertaInternational Society of NephrologyNational Health and Medical Research CouncilBioCrystFresenius Medical Care North AmericaAstraZenecaEli Lilly and CompanyHeart and Stroke Foundation of CanadaServierAmgen
KeywordsMedicineBusinessHealth carePopulationCinacalcetGlobal healthDeveloping countryKidney diseaseFamily medicineEnvironmental healthEconomic growthPublic healthNursingInternal medicineParathyroid hormoneSecondary hyperparathyroidismEconomics

Abstract

fetched live from OpenAlex

A core feature of universal health coverage is equitable access to affordable care not exposing people to financial hardship. This study aims to provide a global overview on availability and access to medications and health technologies for delivery of optimal kidney care. An international survey of stakeholders (clinicians, policymakers, and patient advocates) from countries affiliated to the International Society of Nephrology was conducted from July to September 2022 on availability of tools and services for all aspects of kidney care and access to essential medications. Of 167 participating countries (97.4% of the global population), there were significant disparities in kidney care funding and service availability. Only 5 (n = 1) and 10% (n = 4) of countries in Latin America and Africa, respectively, publicly funded non-dialysis CKD care free at the point of delivery, compared to73% (n = 16) in Western Europe. Public funding (and free at point of delivery) for medications for dialysis and kidney transplantation was available in only 24% (n = 39) and 30% (n = 50) of countries worldwide, with the proportion increasing in line with country income levels. There was reduced capacity for the management of CKD mineral bone disease in low-income countries (LICs) - serum parathyroid hormone was available in only 26% (n = 5) of LICs and the ability to administer non-calcium-based phosphate binders and cinacalcet was also very limited in LICs [16% (n = 3) and 5% (n = 1), respectively]. Nutritional services like oral supplements were accessible in 32% (n = 6) of LICs versus 97% (n = 61) of high-income countries. This study highlights significant gaps in the global methods of funding and availability of medications, capacity for kidney disease monitoring, and capacity to treat complications of kidney disease to improve outcomes. Achieving universal and equitable access to essential medications and health technologies for kidney care is vital to tackle the rapidly growing global burden of kidney disease.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.004
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.701
Threshold uncertainty score0.993

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.004
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.041
GPT teacher head0.367
Teacher spread0.326 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2025
Admission routes2
Has abstractyes

Explore more

Same venuePLOS Global Public HealthSame topicChronic Kidney Disease and DiabetesFrench-language works237,207